Month: March 2022

Reports Quarterly and Annual Investment Income of $17.6 and $71.4 Million, Respectively Record Quarterly Origination Volume of $216 Million Conference Call Today, Thursday, March 3 at 6:00 p.m. ET WOODSIDE, Calif., March 03, 2022 (GLOBE NEWSWIRE) — Runway Growth Finance Corp. (Nasdaq: RWAY) (“Runway Growth” or the “Company”), a leading provider of flexible capital solutions to late-stage and growth companies seeking an alternative to raising equity, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2021. Fourth Quarter 2021 HighlightsNet investment income (“NII”) of $10.9 million, or $0.28 per share Annualized portfolio yield on debt investments of 14.0% for the quarter Six investments funded totaling $188.9 million across three new and three existing portfolio companies Aggregate...

ISSAQUAH, Wash., March 03, 2022 (GLOBE NEWSWIRE) — Costco Wholesale Corporation (“Costco” or the “Company”) (Nasdaq: COST) today announced its operating results for the second quarter (twelve weeks) and the first 24 weeks of fiscal 2022, ended February 13, 2022. Net sales for the quarter increased 16.1 percent, to $50.94 billion, from $43.89 billion last year. Net sales for the first 24 weeks increased 16.4 percent, to $100.35 billion, from $86.23 billion last year. Comparable sales for the second quarter and first 24 weeks of fiscal 2022 were as follows:                     12 Weeks   12 Weeks   24 Weeks   24 Weeks        Adjusted*       Adjusted*  U.S. 15.8%   11.3%   15.4%   10.6%  Canada 16.0%   12.4%   16.6%   10.3%  Other International 6.2%   9.0%   9.5%   9.9%                   Total Company 14.4%   11.1%   14.7%   10.5%                   E-commerce 12.5%   12.6%   13.3%   12.9%                 *Excluding...

Robust Revenue Growth Across All Operating SegmentsBalance Sheet & Liquidity Remain StrongFY22 Guidance Points to Another Record Year of Revenue and Earnings HOUSTON, March 03, 2022 (GLOBE NEWSWIRE) — Quanex Building Products Corporation (NYSE:NX) (“Quanex” or the “Company”) today announced its results for the three months ended January 31, 2022.   The Company reported the following selected financial results:    Three Months Ended January 31,($ in millions, except per share data)   2022   2021Net Sales   $267.0   $230.1Gross Margin   $55.2   $53.8Gross Margin %   20.7%   23.4Net Income   $11.2   $7.9Diluted EPS   $0.34   $0.24         Adjusted Net Income   $11.3   $9.0Adjusted Diluted EPS   $0.34   $0.27Adjusted EBITDA   $24.4   $24.3Adjusted EBITDA Margin %   9.1%   10.6%         Cash...

SAN RAMON, Calif., March 03, 2022 (GLOBE NEWSWIRE) — CooperCompanies (NYSE: COO) today announced financial results for its first quarter of fiscal year 2022, which ended January 31, 2022.Revenue increased 16% year-over-year to $787.2 million. CooperVision (CVI) revenue up 11% to $561.5 million, and CooperSurgical (CSI) revenue up 30% to $225.7 million. GAAP diluted earnings per share $1.91, from $42.31 in last year’s first quarter due to a significant deferred tax benefit recorded in the prior year period. Non-GAAP diluted earnings per share $3.24, up $0.07 or 2% from last year’s first quarter. See “Reconciliation of Selected GAAP Results to Non-GAAP Results” below.Commenting on the results, Al White, Cooper’s President and CEO said, “Cooper reported a strong start to fiscal 2022 with CooperVision...

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) — First Eagle Alternative Capital BDC, Inc. (NASDAQ: FCRD) (“First Eagle Alternative Capital BDC” or the “Company”), a direct lender to middle market companies, today announced financial results for its fourth fiscal quarter and year ended December 31, 2021. Additionally, the Company announced that its Board of Directors (the “Board”) has declared a first fiscal quarter 2022 dividend of $0.10 per share payable on March 31, 2022, to stockholders of record as of March 15, 2022. HIGHLIGHTS($ in millions, except per share amounts)  Portfolio results As of Dec. 31, 2021  Total assets $417.8    Investment portfolio, at fair value $392.1    Net assets $190.7    Net asset value per share $6.34    Weighted average yield on investments   6.5 %    Year ended Dec. 31, 2021 Quarter...

– Approximately $113 Million of U.S. Product Sales in 2021 – – Approximately $13 Million of International Product Sales in 2021 – – Corporate Update Conference Call Today at 4:30 PM ET – NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2021. “SIGA’s fourth quarter and annual financial results are highlighted by approximately $113 million of product sales in connection with deliveries of oral TPOXX® to the U.S. government,” said Phil Gomez, CEO of SIGA. “With many industries, including the pharmaceutical industry, facing significant supply chain challenges, the delivery of approximately $125 million of oral TPOXX to the U.S. and Canadian...

-Top-line data readout from TERN-201 (VAP-1 inhibitor) clinical trial in NASH expected in March 2022 -Initiation of Terns’ first NASH trial of TERN-501 (THR-β agonist) alone and in combination with TERN-101 (FXR agonist) planned for first half of 2022 with top-line data expected in second half of 2023 -Nominated TERN-601 (GLP-1 receptor agonist) development candidate with the goal of initiating a first-in-human clinical trial in 2023 -Cash and equivalents of $166 million provides runway into 2024 FOSTER CITY, Calif., March 03, 2022 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases, such as non-alcoholic steatohepatitis (NASH) and...

– Quarter-end cash position of $140.2 million provides runway to complete all ongoing and planned clinical trials of milademetan, including an ample cash cushion for the Phase 3 MANTRA trial in liposarcoma – – Enrollment in both Phase 3 liposarcoma trial (MANTRA) and Phase 2 basket trial (MANTRA-2) are on schedule, all site activations anticipated by the end of the first quarter 2022 – – Rain entered into a clinical supply agreement with Roche for the supply of atezolizumab for a planned Phase 1 trial (MANTRA-4) combination study of milademetan and atezolizumab in patients with CDKN2A loss and p53 wildtype advanced cancers – – Management to host conference call and webcast today at 4:30 PM Eastern Time – NEWARK, Calif., March 03, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing...

PONTE VEDRA, Fla., March 03, 2022 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights:Revenue of $33.4 million in the fourth quarter 2021, a 39% increase over the same period last year and a 55% increase sequentially. Full year 2021 revenue of $94.4 million, a 65% increase over 2020. Gross margin of 81.1% in the fourth quarter 2021, an increase of 220 basis points from the same period last year. Full year 2021 gross margin of 81.1%, an increase of 285 basis points over 2020. Increased strategic investments in our sales and marketing programs, including...